Tarek Kudaimi, MD
Rheumatology · Munster, INNPI 1689638033
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 53.9% of the total. 2025 is the largest year on record at $1,041, 2.3 times the $449 reported in 2019. That places this record below the midpoint for rheumatology clinicians in IN, where the typical reported total is $2,585.
Across 126 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$511
- Janssen Scientific Affairs, LLC$105
- Johnson & Johnson$82
- Mallinckrodt Hospital Products Inc.$57
- Sanofi$40
- plus $378 from 18 others
What the payments were for
- Food & beverage$2,48898%
- Education$532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 76 | $1,369 |
| Amgen(2 entities) | 16 | $511 |
| Janssen Scientific Affairs, LLC | 1 | $105 |
| Johnson & Johnson | 5 | $82 |
| Mallinckrodt Hospital Products Inc. | 2 | $57 |
| Sanofi | 2 | $40 |
| AstraZeneca | 2 | $35 |
| Lilly USA, LLC | 2 | $32 |
| Aurinia Pharma U.S., Inc. | 1 | $31 |
| Sobi, Inc | 1 | $30 |
| Novartis | 1 | $27 |
| GSK | 2 | $27 |
| Pfizer | 2 | $26 |
| Organon | 3 | $21 |
| Dexcom, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Sebela Pharmaceuticals Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $13 |
| Bristol Myers Squibb | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$266
- Skyrizi$125
- STELARA$105
- SIMPONI ARIA$105
How this compares
$2,541 in reported general payments places this provider in the 45th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 151 | $1,178,181 |
| Humira(Cf) PenAdalimumab | 136 | $1,089,790 |
| RinvoqUpadacitinib | 40 | $258,350 |
| Humira PenAdalimumab | 20 | $218,322 |
| Xeljanz XrTofacitinib Citrate | 27 | $162,899 |
| EnbrelEtanercept | 25 | $131,723 |
| OtezlaApremilast | 26 | $122,146 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $115,957 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 17 | $112,372 |
| XeljanzTofacitinib Citrate | 20 | $111,100 |
| KevzaraSarilumab | 18 | $86,592 |
| Taltz AutoinjectorIxekizumab | 12 | $81,356 |
| BenlystaBelimumab | 13 | $74,787 |
| Humira(Cf)Adalimumab | 11 | $71,101 |
| Actemra ActpenTocilizumab | 14 | $61,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,369 | $329,45151 claims |
| AmgenEnbrel, Otezla | $511 | $253,86951 claims |
| PfizerXeljanz | $26 | $111,10020 claims |
| SanofiKevzara | $40 | $86,59218 claims |
| GSKBenlysta | $27 | $74,78713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 106 rheumatology providers in Indiana.
Other rheumatology in Munster
- Anita ZachariahMunster$37K
- John ByunMunster$3K
- James DreyfusMunster$3K
- David BattIndianapolis$577K
- Kathleen ThomasNoblesville$511K
- Keith ReichDyer$193K
- Douglas SmithIndianapolis$147K
- Ahmad SalahMerrillville$139K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.